Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Abstract Background Pegylated liposomal doxorubicin plays an important role in the treatment of patients with severe refractory human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). High cumulative doses of conventional doxorubicin exceeding 500 mg/m2 are known to cause cardiac toxicity...

Full description

Bibliographic Details
Main Authors: Ayaka Ishihara, Shuji Hatakeyama, Jun Suzuki, Yusuke Amano, Teppei Sasahara, Masaki Toshima, Yuji Morisawa
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Infectious Diseases
Subjects:
Human immunodeficiency virus infection
Kaposi sarcoma
Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome
Pegylated liposomal doxorubicin
Cardiac toxicity
Online Access:http://link.springer.com/article/10.1186/s12879-019-4500-7

Internet

http://link.springer.com/article/10.1186/s12879-019-4500-7

Similar Items